236 related articles for article (PubMed ID: 18422070)
1. [Treatment of hematologic neoplasms during pregnancy].
Tartas NE; Foncuberta MC; Avalos JC
Medicina (B Aires); 2007; 67(6 Pt 2):729-36. PubMed ID: 18422070
[TBL] [Abstract][Full Text] [Related]
2. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
3. Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy.
Meera V; Jijina F; Shrikande M; Madkaikar M; Ghosh K
Leuk Res; 2008 Oct; 32(10):1620-2. PubMed ID: 18420270
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report.
Buyukbayrak EE; Ergen B; Karsidag YK; Kars B; Turan C; Argon D
Arch Gynecol Obstet; 2008 Aug; 278(2):161-3. PubMed ID: 18193246
[TBL] [Abstract][Full Text] [Related]
5. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
6. Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy.
Kobayashi Y
Jpn J Clin Oncol; 2011 Feb; 41(2):157-64. PubMed ID: 21113055
[TBL] [Abstract][Full Text] [Related]
7. Persistence of molecular remission throughout pregnancy in CML after imatinib.
Sorà F; De Matteis S; Bajer J; D'alò F; Leone G; Sica S
Leuk Res; 2009 Jun; 33(6):e6-7. PubMed ID: 18937976
[No Abstract] [Full Text] [Related]
8. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
9. [Pharmacogenetics and tailored drug therapy].
Nielsen FC; Borregaard N
Ugeskr Laeger; 2009 Mar; 171(10):790-4. PubMed ID: 19265602
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Hayashi Y
Gan To Kagaku Ryoho; 2007 Feb; 34(2):194-202. PubMed ID: 17301526
[TBL] [Abstract][Full Text] [Related]
11. [Hematologic neoplasms and pregnancy].
Tartas N; Chacón R; Sánchez Avalos JC
Medicina (B Aires); 1995; 55(2):155-8. PubMed ID: 7565054
[TBL] [Abstract][Full Text] [Related]
12. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
13. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
Inokura K; Onishi Y; Shimosegawa K; Okitsu Y; Katsuoka Y; Fujiwara T; Fukuhara N; Ishizawa K; Harigae H
Ann Hematol; 2012 Nov; 91(11):1825-6. PubMed ID: 22543830
[No Abstract] [Full Text] [Related]
14. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate for the treatment of chronic myeloid leukemia.
Soverini S; Martinelli G; Iacobucci I; Baccarani M
Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
[TBL] [Abstract][Full Text] [Related]
16. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Hwang YY; Tse E; So JC; Wan TS; Kwong YL
Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
[No Abstract] [Full Text] [Related]
17. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
19. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
Ouyang Z; DU QF; Liu XL; Zhang S; Zhu HQ; Gong JM; Song LL; Ouyang LY; Liu Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):704-6. PubMed ID: 18504184
[TBL] [Abstract][Full Text] [Related]
20. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
Breccia M; Alimena G
Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
